MYOF and neoplasm: Patients with a predominant MYOFlow stroma showed nearly doubled median overall survival (31.86 months) compared to patients with MYOFhigh stroma (16.09 months) (Fig. 1J), supporting the implication of myoferlin in tumor fibrosis and potential tumor-promoting functions of the MYOFhigh TME.